CTFP October 2021

Instagram Youtube LinkedIn Facebook Twitter

 

Clinical Thyroidology® for the Public

Table of Contents

EDITOR’S COMMENTS

Welcome to another issue issue of Clinical Thyroidology for the Public. In this journal, we will bring to you the most up-to-date, cutting edge thyroid research. We also provide even faster updates of late-breaking thyroid news through Twitter at @thyroidfriends and on Facebook. Our goal is to provide patients with the tools to be the most informed thyroid patient in the waiting room. Also check out our friends in the Alliance for Thyroid Patient Education. The Alliance member groups consist of: the American Thyroid Association, Bite Me Cancer, the Graves’ Disease and Thyroid Foundation, the Light of Life Foundation, MCT8 – AHDS Foundation, ThyCa: Thyroid Cancer Survivors’ Association, Thyroid Cancer Canada, Thyroid Cancer Alliance and Thyroid Federation International.

We invite all of you to join our Friends of the ATA community. It is for you that the American Thyroid Association (ATA) is dedicated to carrying out our mission of providing reliable thyroid information and resources, clinical practice guidelines for thyroid detection and treatments, resources for connecting you with other patients affected by thyroid conditions, and cutting edge thyroid research as we search for better diagnoses and treatment outcomes for thyroid disease and thyroid cancer. We thank all of the Friends of the ATA who support our mission and work throughout the year to support us. We invite you to help keep the ATA mission strong by choosing to make a donation that suits you — it takes just one moment to give online at: www.thyroid.org/donate and all donations are put to good work. The ATA is a 501(c)3 nonprofit organization and your gift is tax deductible.

While the Covid-19 pandemic is winding down, it has caused an unprecedented upheaval in our daily lives and presented extremely difficult challenges to our healthcare system. We at the American Thyroid Association would like to make sure that you all have access to most accurate, reliable, fact-based and updated information. (https://www.thyroid.org/covid-19/)

October is Thyroid Nodule Awareness Month.

In this issue, the studies ask the following questions:

  • Can a web-based tool help manage treatment decisions for thyroid nodules
  • What are the predictors or cancer recurrence in patients with follicular thyroid cancer?
  • Can repeat biopsies of indeterminate nodules decrease the risk of molecular marker testing?
  • What is the major factor in treatment decision-making in Graves’ disease?
  • What is the best way to dose radioactive iodine for Graves’ disease?
  • Are liquid or gel-based formulations for levothyroxine better absorbed than tablets?

We welcome your feedback and suggestions. Let us know what you want to see in this publication. I hope you find these summaries interesting and informative.

Alan P. Farwell, MD